Online Reporter
Herald Reporter
THE Medicines Control Authority of Zimbabwe (MCAZ) has granted fast-tracked approval to Lenacapavir, a long-acting injectable for HIV prevention, a development rights groups have described as a crucial step towards an Aids-free generation.
The drug, which requires only two injections per year, is a new-generation pre-exposure prophylaxis (PrEP) option expected to improve adherence among high-risk populations.
In statements following the regulatory announcement, organisations representing girls, women and sex workers tempered their optimism with a call for equitable access.
Precious Msindo of Springs of Life Zimbabwe cautioned that the approval’s impact hinges on its implementation. She cited structural barriers such as criminalisation, stigma and police harassment that often prevent sex workers from accessing existing health services.
“Meaningful community consultation is essential. Sex workers understand their own realities. We must be included in planning, messaging and monitoring the rollout. Nothing about us without us,” Msindo stated.
Ekenia Chifamba of Shamwari Yemwanasikana said protecting the rights of young women and girls is a prerequisite for the drug’s success, emphasising that medical innovation must be paired with social support.
Both leaders urged the Ministry of Health and international partners to ensure the rollout includes community-led delivery models and non-discriminatory service provision.
